81 related articles for article (PubMed ID: 5084947)
21. Use of the antibody-dependent cellular cytotoxicity test to detect antibodies in sera of breast cancer patients.
Plain MJ; Whitehead RH; Jose DG
J Natl Cancer Inst; 1981 Apr; 66(4):619-24. PubMed ID: 7014964
[TBL] [Abstract][Full Text] [Related]
22. Horizontal studies of cell mediated immune reactions to autologous tumour antigens in patients with operable mammary carcinoma.
Jones BM; Turnbull AR
Br J Cancer; 1975 Sep; 32(3):339-44. PubMed ID: 1233078
[TBL] [Abstract][Full Text] [Related]
23. Cell-mediated immunity in patients with malignant melanoma.
Mackie RM; Spilg WG; Thomas CE; Cochran AJ
Br J Dermatol; 1972 Dec; 87(6):523-8. PubMed ID: 4648800
[No Abstract] [Full Text] [Related]
24. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
25. Regarding breast cancer as an immunologically responsive tumor.
Mitchell MS
Proc Assoc Am Physicians; 1995 Oct; 107(3):279-87. PubMed ID: 8608412
[No Abstract] [Full Text] [Related]
26. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas.
Gnjatic S; Cai Z; Viguier M; Chouaib S; Guillet JG; Choppin J
J Immunol; 1998 Jan; 160(1):328-33. PubMed ID: 9551988
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical reactivity of anti-melanoma monoclonal antibody 225.28S in human breast cancer biopsies.
Dell'Erba L; Calo-Gabrieli G; Caruso ML; Thomas R; Cortino G; Valentini AM; Muto P; Albrizio M; Pastena MI; Lastoria S
Anticancer Res; 2001; 21(2A):925-30. PubMed ID: 11396186
[TBL] [Abstract][Full Text] [Related]
28. [Cellular immunity in surgically treated cancer patients].
Adorján I; Csonka C; Czakó T; Assefa AJ; Papp Z; Gergely M
Orv Hetil; 1982 Mar; 123(10):595-7. PubMed ID: 7070800
[No Abstract] [Full Text] [Related]
29. [Standardized recall antigen testing in patients with malignant melanoma, endogenous eczema patients and healthy humans].
Stenger D; Delbrück H; Krumrey K; Zaun H
Z Hautkr; 1983 Mar; 58(5):293-304. PubMed ID: 6845797
[TBL] [Abstract][Full Text] [Related]
30. In vitro detection of cellular immunity to melanoma antigens in man by the monocyte spreading inhibition test.
Mazuran R; Mujagic H; Malenica B; Silobrcic V
Int J Cancer; 1976 Jan; 17(1):14-20. PubMed ID: 1248899
[TBL] [Abstract][Full Text] [Related]
31. Leukocyte adherence inhibition: tumor specificity of cellular and serum-blocking reactions in human melanoma, breast cancer, and colorectal cancer.
Halliday WJ; Koppi TA; Khan JM; Davis NC
J Natl Cancer Inst; 1980 Aug; 65(2):327-35. PubMed ID: 6157045
[TBL] [Abstract][Full Text] [Related]
32. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
33. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
[TBL] [Abstract][Full Text] [Related]
34. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
Ramirez-Montagut T; Turk MJ; Wolchok JD; Guevara-Patino JA; Houghton AN
Oncogene; 2003 May; 22(20):3180-7. PubMed ID: 12789294
[TBL] [Abstract][Full Text] [Related]
35. [Clinical aspects of the study of neoplastic antigens].
Lisiewicz J; Moszczyński P
Pol Tyg Lek; 1984 Feb; 39(6):201-4. PubMed ID: 6204325
[No Abstract] [Full Text] [Related]
36. Evaluation of the LAI test in patients with benign and malignant breast diseases.
Kovarík J; Lauerová L; Ninger E; Munzarová M; Feit J; Zemanová D; Wotke R
Neoplasma; 1983; 30(2):163-7. PubMed ID: 6843721
[TBL] [Abstract][Full Text] [Related]
37. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
38. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
Wang RF; Johnston SL; Zeng G; Topalian SL; Schwartzentruber DJ; Rosenberg SA
J Immunol; 1998 Oct; 161(7):3598-606. PubMed ID: 9759882
[TBL] [Abstract][Full Text] [Related]
39. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.
Anichini A; Vegetti C; Mortarini R
Cancer Immunol Immunother; 2004 Oct; 53(10):855-64. PubMed ID: 15175905
[TBL] [Abstract][Full Text] [Related]
40. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
